Mannitol and renal graft injury in patients undergoing deceased donor renal transplantation – a randomized controlled clinical trial

摘要

BACKGROUND:Ischaemia/reperfusion (I/R) injury is associated with renal tissue damage during deceased donor renal transplantation. The effect of mannitol to reduce I/R injury during graft reperfusion in renal transplant recipients is based on weak evidence. We evaluated the effect of mannitol to reduce renal graft injury represented by 16 serum biomarkers, which are indicators for different important pathophysiological pathways. Our primary outcome were differences in biomarker concentrations between the mannitol and the placebo group 24?h after graft reperfusion. Additionally, we performed a linear mixed linear model to account biomarker concentrations before renal transplantation.METHODS:Thirty-four patients undergoing deceased donor renal transplantation were randomly assigned to receive either 20% mannitol or 0.9% NaCl placebo solution before, during, and after graft reperfusion. Sixteen serum biomarkers (MMP1, CHI3L1, CCL2, MMP8, HGF, GH, FGF23, Tie2, VCAM1, TNFR1, IGFBP7, IL18, NGAL, Endostatin, CystC, KIM1) were measured preoperatively and 24?h after graft reperfusion using Luminex assays and ELISA.RESULTS:Sixteen patients in each group were analysed. Tie2 differed 24?h after graft reperfusion between both groups (p?=?0.011). Change of log2 transformed concentration levels over time differed significantly in four biomarkers (VCAM1,Endostatin, KIM1, GH; p?=?0.007; p?=?0.013; p?=?0.004; p?=?0.033; respectively) out of 16 between both groups.CONCLUSION:This study showed no effect of mannitol on I/R injury in patients undergoing deceased renal transplantation. Thus, we do not support the routinely use of mannitol to attenuate I/R injury.TRIAL REGISTRATION:NCT02705573 . Registered on 10th March 2016.